Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from ...

Crinetics’ acromegaly treatment will go up against several entrenched medicines. Elsewhere, Bristol Myers moved to sell Sotyktu online at a discount and regulators rejected a new version of Biogen’s ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

The French pharma’s venture arm will use the funds to back companies working in immunology, neurology, rare diseases and vaccines.

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

Recent changes to federal guidance on COVID vaccinations have providers worried about what’s to come. “We have opened a door ...